AbCellera presents preclinical data on PSMA x CD3 T-cell engagers

AbCellera (ABCL) announced new data on its PSMA x CD3 T-cell engagers, presented as a poster at the American Association for Cancer Research 116th Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois, taking place April 25 to 30. In its poster presentation at AACR, AbCellera demonstrated that its PSMA x CD3 TCEs show “promising preclinical activity,” the company stated. “The preclinical data package presented at AACR is the first demonstration that our novel CD3-binders can be used to generate molecules with potent anti-tumor efficacy in vivo,” said Adam Clarke, Ph.D., SVP, Discovery at AbCellera. “The poster underscores the strength of our TCE platform strategy, which is to combine diverse CD3- and tumor-binding antibodies and use empirical testing to engineer optimized therapeutic candidates. In addition, the data strongly support the use of costimulation to further increase anti-tumor activity.”